Evidence map›Paper›PMID 17264461›Full record

ArticleIndian journal of pediatrics2007

Beneficial effects of rituximab therapy for systemic lupus erythematosus.

Shina Menon, Pankaj Hari, Arvind Bagga

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Indian journal of pediatrics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shina MenonDivision of Pediatric Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Pankaj Hari
Arvind Bagga
All India Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report an 11-yr-old girl with systemic lupus erythematosus (SLE) with recurrent flares of skin and systemic manifestations, which were poorly controlled with conventional therapy. Treatment with rituximab, a monoclonal antibody against CD20, was associated with remission of symptoms and a steroid sparing effect that persisted for more than 9 months. Therapy with rituximab appears promising in subjects with SLE.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedChildDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansImmunologic FactorsInfusions, IntravenousLupus Erythematosus, SystemicRisk FactorsRituximabSeverity of Illness IndexTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedImmunologic FactorsRituximab

Identifiers

PMID17264461
OpenAlexW2060981012

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.